Merck & Co. Share Buybacks decreased by 30.2% to $874.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 24.9%, from $1.16B to $874.00M. Over 4 years (FY 2021 to FY 2025), Share Buybacks shows an upward trend with a 56.8% CAGR.
High repurchases often signal management's confidence in the company's valuation or a strategy to improve earnings per share.
The cash outflow associated with the company buying back its own shares from the open market. This is a primary method f...
Common among mature, cash-generative companies; peers in the healthcare sector often balance this with R&D investment.
share_repurchases| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $239.00M | $583.00M | $18.00M | $0.00 | $0.00 | $0.00 | $0.00 | $149.00M | $338.00M | $466.00M | $393.00M | $122.00M | $251.00M | $444.00M | $489.00M | $1.16B | $1.35B | $1.32B | $1.25B | $874.00M |
| QoQ Change | — | +143.9% | -96.9% | -100.0% | — | — | — | — | +126.8% | +37.9% | -15.7% | -69.0% | +105.7% | +76.9% | +10.1% | +138.0% | +15.5% | -1.6% | -5.4% | -30.2% |
| YoY Change | — | — | — | — | -100.0% | -100.0% | -100.0% | — | — | — | — | -18.1% | -25.7% | -4.7% | +24.4% | +854.1% | +435.9% | +198.0% | +156.0% | -24.9% |